Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
341. |
ECCT/21/12/05 | 131 Inclacumab Ph 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease… read more |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Fredrick Asirwa Chite 3. Videlis N Nduba 4. Prof. Jessie N Githanga Site(s) in Kenya… read more |
View |
342. |
ECCT/21/07/03 | GBT_131 Inclacumab-Ps 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease… read more |
Principal Investigator(s) 1. Prof Jessie N Githanga 2. Fredrick Sirwa Chite 3. Bernhards Ragama Ogutu 4. Videlis N Nduba Site(s) in Kenya… read more |
View |
343. |
ECCT/21/11/08 | GBT_131 Inclacumab-Ps 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease… read more |
Principal Investigator(s) 1. Videlis N Nduba 2. Prof. Jessie N Githanga 3. Fredrick Sirwa Chite 4. Bernhards Ragama Ogutu Site(s) in Kenya… read more |
View |
344. |
ECCT/21/11/04 | GBT_131 Inclacumab-Ps 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease… read more |
Principal Investigator(s) 1. Fredrick Sirwa Chite 2. Prof Jessie N Githanga 3. Bernhards Ragama Ogutu 4. Videlis N Nduba Site(s) in Kenya… read more |
View |
345. |
ECCT/19/05/01 | A randomized, double-blinded, placebo-controlled, dose-escalation phase 1 clinical trial to evaluate the safety and immunogenicity of recombinant HIV envelope protein BG505 SOSIP.664 gp140 Vaccine, Adjuvanted, in… read more |
Principal Investigator(s) 1. Omu Anzala Site(s) in Kenya KAVI-ICR KNH SITE |
View |